ClinicalTrials.gg
RecruitingNCT06514365Updated Jul 23, 2024

Comparison of the Analgesic Effect of Subsartorial Saphenous Block and Popliteal Sciatic vs Subsartorial Saphenous Block and IPACK in Total Knee Replacement Surgery.

An interventional study of IPACK block with Bupivacaine 0.25% with adrenaline in Pain, Acute, Knee Osteoarthritis and Anesthesia, sponsored by Germans Trias i Pujol Hospital. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-23.

Sponsored by Germans Trias i Pujol Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Acute Pain with a site in Spain — 4 open to participants now, 5 under way, none of them phase 3. Acute Pain · Spain.

Planned enrollment
16th of 19
62 · median 160
Started
2020
with 1 other
No phase
11 of 20
4 open now
Registered
9th of 20
by date
Lead sponsor
1 of 20
Germans Trias i Pujol Hospital

Among the 20 studies in Acute Pain with a site in Spain, this one is the 16th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2020, is one of 11 with no phase, and was the 9th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

4 of the 20 studies in Acute Pain with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Acute Pain with a site in Spain, or all of them as a file.
02

Study summary

Total knee replacement surgery is associated with significant pain in the immediate postoperative period, especially in movement. In turn, this is associated with more subsequent chronic pain.

There are multiple options and the tendency is to perform increasingly distal nerve blocks to minimize limb weakness and thus allow early rehabilitation. In 2012, in an oral communication, Sanjay Sinha described a new nerve block called iPACK ("Interspace between the Popliteal Artery and the Capsule of the posterior Knee"). There are few studies on the efficacy of such a blockade so far, but none comparing the groups saphene + sciatic blocks vs. saphene + iPACK blocks.

Therefore, this study aims to provide more information on the effectiveness this nerve blocks, in total knee replacement, in terms of analgesia and motor function.

03

Conditions studied

  • Pain, Acute
  • Knee Osteoarthritis
  • Anesthesia

Keywords

  • Ipack
  • Block
  • Total knee replacement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with osteoarthritis scheduled for total primary knee arthroplasty with same surgeons
  • Locoregional anesthesia
  • Age equal to or greater than 18 years
  • Consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years old
  • General anesthesia
  • Allergy to local anesthetics
  • Severe kidney failure (Cr ≥ 2mg / dL)
  • Chronic opioid use (over 3 months)
  • Chronic pregabalin / gabapentin use (more than 3 months)
  • Psychiatric illness that may interfere with the evaluation or follow-up
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Echo-guided IPACK block

    IPACK block using 0.25% bupivacaine 15mL with adrenaline once.

    Drug: IPACK block with Bupivacaine 0.25% with adrenaline

  • Active comparator
    Echo-guided sciatic block

    Sciatic nerve block using 0.25% bupivacaine 15mL with adrenaline once.

    Drug: IPACK block with Bupivacaine 0.25% with adrenaline

Interventions

  • DrugIPACK block with Bupivacaine 0.25% with adrenaline

    The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.

    Also known as: Interspace between the Popliteal Artery and the Capsule of the posterior Knee

06

What researchers measure

Primary outcomes

  1. Pain at rest

    Measured by the numerical visual scale at 6 hours after intradural anesthesia, minimum of 0 and maximum of 10, where means no pain and 10 means the worst pain in the life of the patient.

    Time frame: 6 hours after surgery

  2. Pain at rest

    Measured by the numerical visual scale at 24 hours after intradural anesthesia, minimum of 0 and maximum of 10, where means no pain and 10 means the worst pain in the life of the patient.

    Time frame: 24 hours after surgery

  3. Pain at rest

    Measured by the numerical visual scale at 48 hours after intradural anesthesia, minimum of 0 and maximum of 10, where means no pain and 10 means the worst pain in the life of the patient.

    Time frame: 48 hours after surgery

  4. Pain at movement

    Measured by the numerical visual scale at 48 hours after intradural anesthesia, minimum of 0 and maximum of 10, where means no pain and 10 means the worst pain in the life of the patient.

    Time frame: 6 hours after surgery

  5. Pain with movement

    Measured by the numerical visual scale at 48 hours after intradural anesthesia, minimum of 0 and maximum of 10, where means no pain and 10 means the worst pain in the life of the patient.

    Time frame: 24 hours after surgery

  6. Pain with movement

    Measured by the numerical visual scale at 48 hours after intradural anesthesia, minimum of 0 and maximum of 10, where means no pain and 10 means the worst pain in the life of the patient.

    Time frame: 48 hours after surgery

  7. Motor block

    Measured on a scale of 3, where 0 = no motor block, 1 = partial motor block and 2 = complete motor block. It will be performed on plantar flexion (distribution of the tibial nerve) and dorsiflexion (peroneal distribution)).

    Time frame: 6 hours after surgery

  8. Motor block

    Measured on a scale of 3, where 0 = no motor block, 1 = partial motor block and 2 = complete motor block. It will be performed on plantar flexion (distribution of the tibial nerve) and dorsiflexion (peroneal distribution)).

    Time frame: 24 hours after surgery

  9. Motor block

    Measured on a scale of 3, where 0 = no motor block, 1 = partial motor block and 2 = complete motor block. It will be performed on plantar flexion (distribution of the tibial nerve) and dorsiflexion (peroneal distribution)).

    Time frame: 48 hours after surgery

Secondary outcomes

  1. Opioids dose

    Measured in milligrams of intravenous morphine hydrochloride daily.

    Time frame: 6 hours after surgery

  2. Opioids dose

    Measured in milligrams of intravenous morphine hydrochloride daily.

    Time frame: 24 hours after surgery

  3. Opioids dose

    Measured in milligrams of intravenous morphine hydrochloride daily.

    Time frame: 48 hours after surgery

  4. Discharge days

    Time to discharge measured in days

    Time frame: Days

  5. Patient satisfaction

    Patient satisfaction on a scale of 0 to 10, where 0 is minimum satisfaction and 10 is maximum satisfaction.

    Time frame: 24 hours after surgery

  6. Ambulation time

    Time to ambulation (measured in hours) from discharge from URPA

    Time frame: Up to 24 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jun 2024, 47 months.

Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 47 months is above that.

Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2020
First posted
Jul 23, 2024
StartActual
Jun 10, 2020
Primary completionActual
Jun 1, 2024
CompletionEst.
Aug 1, 2024
Last update
Jul 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06514365
Lead sponsor
Germans Trias i Pujol Hospital
Responsible party
Dinu (Principal Investigator, Germans Trias i Pujol Hospital) — Principal investigator
First posted
Jul 23, 2024
Start date
Jun 10, 2020
Primary completion
Jun 1, 2024
Completion
Aug 1, 2024 (estimated)
Last update
Jul 23, 2024

Study contacts

Madalina Dinu, Mrs
Contact
madidinu@hotmail.com
0034600349517

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion